BioMerieux

BioMérieux was founded in 1963 as a family-owned company and is headquartered in France. The company develops and produces vitro diagnostics solutions and offers related systems, reagents, software and services. Company solutions include clinical applications, as well as solutions for the agri-food, cosmetics and pharmaceutical industries. Company customers are private and include hospital laboratories that focus on the diagnosis of infectious diseases. The company and its 11,200 employees work in 43 countries and serve more than 160 countries with the support of a large distributors’ network. Biomerieux operates 19 production sites and 20 R&D sites. Company solutions help doctors to manage contamination risks and make informed decisions based on the results that are obtained from a patient sample (such as blood, urine, stool, cerebrospinal fluid, saliva, etc.). It provides efficient solutions for the enumeration of microbial flora, the monitoring of air and surface quality, sterility testing, the detection of specific pathogenic bacteria, and more. BioMérieux is listed on NYSE Euronext Paris. In fiscal 2018, the company reported € 2.4 billion in sales and during the first quarter of fiscal 2019, the company announced an organic growth of 3.8%. Trade this instrument and tune in for regularBIM.PAprice updates.